---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-039171"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:24:05.741219+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Blue Water Biotech Q1 net loss $2.8M, cash $20.3M, ENTADFI acquisition closed

## Summary
- Net loss of $2.8M in Q1 2023 vs $2.1M in Q1 2022; cash $20.3M, down from $25.8M at Dec 2022.
- Acquired ENTADFI (FDA-approved BPH treatment) for up to $100M; $20M upfront payable in tranches through Sep 2024.
- Appointed Frank Jaeger as SVP Marketing & Business Development for ENTADFI launch; Timothy Ramdeen joined board.
- Partnered with AbVacc to develop vaccine candidates targeting monkeypox and Marburg using norovirus VLP platform.
- Signed research agreement with UT Health San Antonio for non-human primate study of Chlamydia vaccine BWV-401.

## SEC filing metadata
- accession: 0001213900-23-039171
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/0001213900-23-039171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/ea178509-8k_bluewater.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-039171
- JSON: https://secwatch.observer/filing/0001213900-23-039171.json
- Plain text: https://secwatch.observer/filing/0001213900-23-039171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.